Solid Tumors
(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
- Details
ClinicalTrials.gov ID:
NCT03822117
Diagnosis Type:
NA
USOR Number:
- Address
910 E 26th St, Suite 200
Minneapolis, MN 55404
P: (612) 884-6300